Description

Glaukos Corporation’s iDose TR Generates $74 Million — Is Glaucoma Care Reaching A Tipping Point?

Glaukos Corporation reported strong financial results for the second quarter of 2026, with consolidated net sales reaching a record $185.6 million, representing a 50% increase year-over-year on a reported basis and 49% in constant currency terms. This robust performance led the company to raise its full-year 2026 net sales guidance to a range of $680 million to $700 million, up from previous guidance of $620 million to $635 million. The growth was broad-based across the company’s key franchises, driven primarily by expansions in their glaucoma and corneal health businesses. In the U.S. glaucoma segment, net sales grew 64% year-over-year to $118.5 million, largely due to increased contributions from the iDose TR therapy, which generated approximately $74 million in sales.